STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

NCT07038915 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped 0 participants

Conditions

Lung Squamous Cell Carcinoma
Anti-PD1/PDL1 Antibody

Interventions

DRUG: Tiragolumab
DRUG: Ivonescimab

Sponsor

M.D. Anderson Cancer Center